Neuroplasticity: mechanisms, human evidence and research limits
A sourced guide to brain change through LTP, BDNF, human studies and preclinical findings, separating biomarkers from clinical benefit.
In-depth, independent articles on neuroscience, cognitive performance and nootropics, with research sources.
A sourced guide to brain change through LTP, BDNF, human studies and preclinical findings, separating biomarkers from clinical benefit.
Dopamine contributes to motivation; L-tyrosine and Mucuna studies do not establish general motivation gains or a safe dopamine protocol for healthy people.
Melatonin, magnesium and other supplements have been studied using different sleep measures; subjective improvement is not proof of deeper sleep or a safe nightly protocol.
Assess product form, study population and drug interactions; beginner trios, titration and on-off schedules are not protocols established for everyone.
Small studies have examined some attention measures; a universal ideal ratio, prevention of caffeine side effects or safe use for everyone has not been established.
Tolerance, dependence and withdrawal are different phenomena. Breaks may be considered for some substances, but there is no validated cycling schedule for all nootropics.
From the microbiome's production of serotonin and GABA to intestinal permeability, from psychobiotics to dietary strategies: a comprehensive look at the cognitive effects of the gut-brain axis.
Explore links between cortisol and cognition; a change in measured cortisol does not prove that an extract prevents brain damage or treats stress in everyone.
Compare evidence and interaction risks for caffeine–L-theanine and other combinations; single-ingredient findings do not prove clinical synergy for every stack.
Explore CoQ10, PQQ, NMN and creatine research; mitochondrial mechanisms do not explain every cause of brain fog or guarantee supplement benefits.
NMN, resveratrol and other compounds are studied for aging mechanisms; no nootropic protocol has been established to slow cognitive decline in humans.
Evidence and drug interactions differ for saffron, St John’s wort, 5-HTP and other supplements; they are not treatments validated to the same extent.
Hormonal cycles and individual symptoms matter, but predictable cognitive rises and falls in every person by phase, or a matching nootropic schedule, are not established.
Physical performance findings are not the same as cognitive benefits. Creatine, L-tyrosine, Rhodiola and caffeine studies are considered with their populations and conditions.
Vitamin D, B12, magnesium and zinc deficiencies need assessment; supplements have not been shown to improve cognition in everyone without a deficiency.